Publications by authors named "E La"
Introduction: Respiratory syncytial virus (RSV) vaccination could improve health equity by protecting individuals who are disproportionally at increased risk of RSV infection and severe RSV-related outcomes. However, limited information is available about RSV-related disparities among United States (US) adults.
Areas Covered: We reviewed US-specific literature regarding disparities across adult populations in having risk factors for severe RSV disease (cardiopulmonary disease, diabetes, liver disease, kidney disease).
Article Synopsis
- Respiratory syncytial virus (RSV) commonly causes respiratory illnesses, especially severe in adults over 60 or those with chronic conditions; a study examined the cost-effectiveness of the RSVPreF3 vaccine for this age group in the US.* -
- A multi-cohort Markov model compared outcomes of not vaccinating versus a one-time vaccination, estimating that vaccinating approximately 52.7 million older adults would save nearly 244,424 quality-adjusted life years (QALYs) at a societal cost of about $4.5 billion over five years.* -
- The analysis indicated that the adjuvanted RSVPreF3 vaccine is cost-effective, with an incremental cost-effectiveness ratio (
Introduction: Respiratory syncytial virus (RSV) is an important cause of lower respiratory tract disease in older adults, resulting in substantial morbidity and mortality.
Methods: This study estimates the public health impact of vaccination with the adjuvanted RSVPreF3 vaccine among adults aged ≥ 60 years in the United States (US). A static, multi-cohort Markov model was used to estimate RSV-related outcomes over a 3-year time horizon for scenarios with and without one-time RSV vaccination.
Respiratory syncytial virus (RSV) is associated with considerable morbidity and mortality among older adults (aged ≥60 years) and adults with certain chronic conditions in the United States (US). Despite this burden, no previous studies have assessed the knowledge, attitudes, and perceptions (KAP) of RSV among these populations. This study evaluates RSV-related KAP among US adults at increased risk of severe RSV infection.
View Article and Find Full Text PDFIntroduction: Immunocompromised (IC) adults are at increased risk of developing herpes zoster (HZ) and HZ-related complications due to therapy or underlying disease. This study evaluated the cost effectiveness of recombinant zoster vaccine (RZV) versus no vaccine for the prevention of HZ in hematopoietic stem cell transplant (HSCT) recipients and other IC adults aged ≥ 18 years in the United States (US).
Methods: A static Markov model simulated cohorts of IC individuals using a 1-year cycle length and 30-year time horizon to estimate the cost effectiveness of RZV.